Verdict94/ 100
Grade A · #1CoreAge Rx
The most honest middle of the market: nationwide access, both molecules at one flat, no-surprise price.
Visit CoreAge RxHead-to-head verdict
CoreAge Rx vs NovoCare Pharmacy
Two GLP-1 providers, compared side by side on The Verdict Score — our published six-factor rubric. Same yardstick, and no score is adjusted for payment.
Published by The GLP-1 Verdict
Pricing sources checked: CoreAge Rx: August 2026 · NovoCare Pharmacy: Check date not recorded
vs
Verdict66/ 100
Grade C · #264NovoCare Pharmacy
Novo Nordisk's first-party direct-to-consumer pharmacy for branded Wegovy (semaglutide).
Visit NovoCare PharmacyThe verdict
Winner: CoreAge Rx
CoreAge Rx takes it with a higher Verdict Score — 94/100 to 66/100 (grade A vs C). Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch. NovoCare Pharmacy still earns its place — shoppers who want branded Wegovy at the lowest manufacturer-direct self-pay price.
The score compares published program terms and features; it does not measure clinical outcomes or predict which treatment will suit you.
Factor by factor
Both scored on the same six factors — see the methodology. The brass bar marks the stronger side on each.
92Real-world results64
92
Real-world results64
97Price honesty52
97
Price honesty52
96Prescriber access92
96
Prescriber access92
88Formulary choice72
88
Formulary choice72
95Cancellation fairness56
95
Cancellation fairness56
93Member support60
93
Member support60
Price, coverage & features
| Metric | CoreAge Rx | NovoCare Pharmacy |
|---|---|---|
| Verdict Score | 94/100 | 66/100 |
| Grade | A | C |
| Semaglutide | $99/mo | From $349/mo (2.4 mg dose, brand-name) |
| Tirzepatide | $149/mo | Not disclosed |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | No | Yes |
CoreAge Rx
What we like
- Flat, all-in monthly price with no intro-rate step-ups after month one
- Both compounded semaglutide and tirzepatide on one account
- Available in all 50 states
- Straightforward, low-friction cancellation
The caveats
- Not the cheapest — flat-price challengers like Trimi Health and Alan Meds undercut its sticker price
- No FDA-approved brand-name option (compounded only)
- Does not yet publicly name its 503A/B pharmacy partner
NovoCare Pharmacy
What we like
- First-party Novo Nordisk pharmacy — the most authoritative branded Wegovy channel
- $199/mo intro pricing on Wegovy 0.25/0.5 mg starter pens (through December 31, 2026), and the Wegovy pill from $149/mo
- $349/mo standard self-pay is well below the ~$1,300/mo retail list price
- Ships to all 50 states with no telehealth-platform middleman fees
- Cold-chain logistics handled directly by Novo Nordisk
The caveats
- Wegovy only — no Ozempic, no tirzepatide, no compounded GLP-1
- Requires an existing Wegovy prescription — no prescribing clinicians or telehealth intake
- No clinical support included — your own prescriber handles titration and side effects
- Manufacturer-set pricing can change at any time
- $199 pen intro covers only the first 2 fills for new patients (through December 31, 2026); maintenance doses are $349/mo ($399 HD)
Our pick — visit
Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch.
Visit CoreAge Rx Read the full CoreAge Rx review →Also worth a look
Shoppers who want branded Wegovy at the lowest manufacturer-direct self-pay price.
Visit NovoCare Pharmacy Read the full NovoCare Pharmacy review →Keep comparing
Neither of these has to be the answer: the rivals we rank against CoreAge Rx cover the 7 programs closest to it, and the same shortlist for NovoCare Pharmacy does the reverse.
More on CoreAge Rx
More on NovoCare Pharmacy
Or browse the full comparison hub, every head-to-head A to Z and the complete rankings.
Pricing, states and verification reflect each provider's public disclosures at last review; the Verdict Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.